| 503 | Humans |
| 334 | Male |
| 287 | Female |
| 265 | Nervous system diseases |
| 252 | Middle Aged |
| 219 | Parkinson disease |
| 207 | Aged |
| 171 | Adult |
| 163 | Parkinson's disease |
| 157 | Human |
| 89 | Parkinson Disease (drug therapy) |
| 76 | Severity of Illness Index |
| 72 | Treatment |
| 70 | Parkinson Disease (physiopathology) |
| 62 | Parkinson Disease (complications) |
| 55 | Parkinson Disease (therapy) |
| 55 | Animals |
| 53 | Antiparkinson Agents (therapeutic use) |
| 52 | Treatment Outcome |
| 51 | Dystonia |
| 51 | Case study |
| 50 | Magnetic Resonance Imaging |
| 44 | Aged, 80 and over |
| 43 | Antiparkinson Agents (adverse effects) |
| 42 | Subthalamic nucleus |
| 42 | Neuropsychological Tests |
| 41 | Levodopa (adverse effects) |
| 39 | Parkinson Disease (diagnosis) |
| 38 | Levodopa (therapeutic use) |
| 37 | deep brain stimulation |
| 37 | Levodopa |
| 37 | Follow-Up Studies |
| 37 | Adolescent |
| 36 | Exploration |
| 36 | Deep Brain Stimulation (methods) |
| 35 | Chemotherapy |
| 34 | Dose-Response Relationship, Drug |
| 33 | Parkinsonism |
| 33 | Electromyography |
| 33 | Deep brain stimulation |
| 32 | Double-Blind Method |
| 31 | Parkinson Disease (psychology) |
| 30 | Dyskinesia |
| 29 | Tremor |
| 29 | Complication |
| 28 | Questionnaires |
| 27 | Time Factors |
| 26 | Young Adult |
| 26 | Parkinson Disease (pathology) |
| 26 | Diagnosis, Differential |
| 25 | Parkinson Disease (epidemiology) |
| 25 | Antiparkinson agent |
| 24 | subthalamic nucleus |
| 24 | Antiparkinson Agents (administration & dosage) |
| 23 | Retrospective Studies |
| 23 | Pathophysiology |
| 23 | Electrodes, Implanted |
| 23 | Drug Therapy, Combination |
| 23 | Disability Evaluation |
| 23 | Diagnosis |
| 22 | Reproducibility of Results |
| 22 | Multiple system atrophy |
| 22 | Levodopa (administration & dosage) |
| 22 | Case-Control Studies |
| 21 | Neurologic Examination |
| 21 | Myoclonus |
| 21 | Brain (pathology) |
| 20 | Dystonia (diagnosis) |
| 20 | Child |
| 19 | dystonia |
| 19 | Prognosis |
| 19 | Nuclear magnetic resonance imaging |
| 19 | Comparative study |
| 19 | Analysis of Variance |
| 18 | Subthalamic Nucleus (physiology) |
| 18 | Neurologic Examination (drug effects) |
| 18 | Mutation |
| 18 | Dyskinesia, Drug-Induced (etiology) |
| 18 | Dominance, Cerebral (physiology) |
| 18 | Age of Onset |
| 17 | levodopa |
| 17 | Subthalamic Nucleus (physiopathology) |
| 17 | Parkinson Disease (surgery) |
| 17 | Parkinson Disease (etiology) |
| 17 | Instrumental stimulation |
| 17 | Drug Administration Schedule |
| 17 | Dopamine agonist |
| 17 | Disease Progression |
| 17 | Basal ganglion |
| 17 | Animal |
| 16 | Electric Stimulation Therapy |
| 16 | Disease Models, Animal |
| 16 | Chorea |
| 16 | Brain Mapping |
| 15 | Psychiatric Status Rating Scales |
| 15 | Prevalence |
| 15 | France |
| 15 | Dopamine (metabolism) |
| 15 | DNA Mutational Analysis |
| 15 | Cognition Disorders (etiology) |
| 14 | Symptomatology |
| 14 | Psychometrics |
| 14 | Prospective Studies |
| 14 | Parkinson Disease (genetics) |
| 14 | Pallidum |
| 14 | Genotype |
| 14 | Dystonia (therapy) |
| 14 | Depression |
| 14 | Brain (vertebrata) |
| 13 | Tremor (etiology) |
| 13 | Toxicity |
| 13 | Thalamus |
| 13 | Statistics, Nonparametric |
| 13 | Movement Disorders (diagnosis) |
| 13 | Globus Pallidus (physiology) |
| 13 | Functional Laterality |
| 13 | Cognition Disorders (diagnosis) |
| 12 | rating scales |
| 12 | Stereotaxic Techniques |
| 12 | Recommendation |
| 12 | Monkey |
| 12 | Magnetic Resonance Imaging (methods) |
| 12 | Long term |
| 12 | Evolution |
| 12 | Evaluation scale |
| 12 | Electrical stimulus |
| 12 | Elderly |
| 12 | Double blind study |
| 12 | Dopamine |
| 12 | Child, Preschool |
| 12 | Cerebral Cortex (physiopathology) |
| 12 | Age Factors |
| 11 | depression |
| 11 | basal ganglia |
| 11 | Thalamus (surgery) |
| 11 | Ropinirole |
| 11 | Phenotype |
| 11 | Parkinson Disease, Secondary (chemically induced) |
| 11 | Mutation (genetics) |
| 11 | Multiple System Atrophy (diagnosis) |
| 11 | Huntington disease |
| 11 | Functional Laterality (physiology) |
| 11 | France (epidemiology) |
| 11 | Family Health |
| 11 | Deep Brain Stimulation |
| 11 | Cognition |
| 11 | Agonist |
| 10 | dyskinesia |
| 10 | Tremor (physiopathology) |
| 10 | Surgery |
| 10 | Subthalamic Nucleus (surgery) |
| 10 | Risk Factors |
| 10 | Reference Values |
| 10 | Quality of Life |
| 10 | Posture |
| 10 | Parkinsonian Disorders (drug therapy) |
| 10 | Motor Activity (physiology) |
| 10 | Longitudinal Studies |
| 10 | Indoles (therapeutic use) |
| 10 | Image Processing, Computer-Assisted |
| 10 | French |
| 10 | Electric Stimulation |
| 10 | Dystonia (physiopathology) |
| 10 | Dopamine Agonists (therapeutic use) |
| 10 | Differential diagnostic |
| 10 | Cross-Sectional Studies |
| 10 | Chorea (diagnosis) |
| 9 | multiple system atrophy |
| 9 | globus pallidus |
| 9 | clinimetrics |
| 9 | Tomography, X-Ray Computed |
| 9 | Substantia Nigra (pathology) |
| 9 | Sleep disorder |
| 9 | Safety |
| 9 | Rats |
| 9 | Polysomnography |
| 9 | Parkinson Disease (radionuclide imaging) |
| 9 | Myoclonus (physiopathology) |
| 9 | Levodopa (pharmacology) |
| 9 | Instrumentation therapy |
| 9 | History, 20th Century |
| 9 | Dystonic Disorders (physiopathology) |
| 9 | Dystonia (etiology) |
| 9 | Deep Brain Stimulation (adverse effects) |
| 9 | Corpus Striatum (drug effects) |
| 9 | Confidence Intervals |
| 9 | Combined Modality Therapy |
| 9 | Chorea (genetics) |
| 9 | Bromocriptine (therapeutic use) |
| 9 | Brain (metabolism) |
| 9 | Antiparkinson Agents (pharmacology) |
| 9 | Animal model |
| 9 | Activities of Daily Living |
| 8 | movement disorders |
| 8 | Videotape Recording |
| 8 | Tremor (therapy) |
| 8 | Syndrome |
| 8 | Reliability |
| 8 | Quality of life |
| 8 | Psychomotor Performance (physiology) |
| 8 | Posture (physiology) |
| 8 | Placebo |
| 8 | Pedigree |
| 8 | Parkinsonian Disorders (etiology) |
| 8 | Pain |
| 8 | Odds Ratio |
| 8 | Neurons (physiology) |
| 8 | Muscle, Skeletal (physiopathology) |
| 8 | Multiple System Atrophy (physiopathology) |
| 8 | Motor system disorder |
| 8 | Globus Pallidus (surgery) |
| 8 | Globus Pallidus (physiopathology) |
| 8 | Gait Disorders, Neurologic (etiology) |
| 8 | Emission tomography |
| 8 | Electrophysiology |
| 8 | Dystonia (complications) |
| 8 | Dyskinesia, Drug-Induced (drug therapy) |
| 8 | Dyskinesia, Drug-Induced (diagnosis) |
| 8 | Dopamine Agonists (adverse effects) |
| 8 | Depression (etiology) |
| 8 | Degeneration |
| 8 | Clinical trial |
| 8 | Chorea (physiopathology) |
| 8 | Brain (surgery) |
| 8 | Brain (physiopathology) |
| 8 | Behavior |
| 7 | transcranial magnetic stimulation |
| 7 | parkinsonism |
| 7 | Validation |
| 7 | Transcranial magnetic stimulation |
| 7 | Tomography, Emission-Computed |
| 7 | Tomography, Emission-Computed, Single-Photon |
| 7 | Stimulation |
| 7 | Sensitivity and Specificity |
| 7 | Review |
| 7 | Reaction Time (physiology) |
| 7 | Rapid eye movement sleep |
| 7 | Positron emission tomography |
| 7 | Piribedil |
| 7 | Parkinsonian Disorders (pathology) |
| 7 | Multiple System Atrophy (pathology) |
| 7 | Movement Disorders (genetics) |
| 7 | Movement Disorders (etiology) |
| 7 | Mice |
| 7 | Mental Status Schedule |
| 7 | International Cooperation |
| 7 | Injections, Intramuscular |
| 7 | Huntington's disease |
| 7 | Guadeloupe |
| 7 | Electromyography (drug effects) |
| 7 | Electroencephalography |
| 7 | Dystonic Disorders (diagnosis) |
| 7 | Dyskinesia, Drug-Induced (physiopathology) |
| 7 | DBS |
| 7 | Cross-Over Studies |
| 7 | Corpus striatum |
| 7 | Corpus Striatum (pathology) |
| 7 | Bromocriptine |
| 7 | Brain (drug effects) |
| 7 | Basal Ganglia (pathology) |
| 7 | Apathy |
| 6 | tremor |
| 6 | piribedil |
| 6 | pathophysiology |
| 6 | dopamine agonists |
| 6 | chorea |
| 6 | Video recording |
| 6 | Video Recording |
| 6 | Validity |
| 6 | Transcranial Magnetic Stimulation |
| 6 | Toxin |
| 6 | Thalamus (physiopathology) |
| 6 | Thalamus (pathology) |
| 6 | Supranuclear ophthalmoplegia |
| 6 | Statistics as Topic |
| 6 | Spinocerebellar ataxia |
| 6 | Risk factor |
| 6 | Restless legs syndrome |
| 6 | Receptors, Dopamine (drug effects) |
| 6 | Reaction Time |
| 6 | Radiopharmaceuticals (diagnostic use) |
| 6 | Progressive supranuclear palsy |
| 6 | Predictive Value of Tests |
| 6 | Postural Balance (physiology) |
| 6 | Point Mutation (genetics) |
| 6 | Photon |
| 6 | Parkinsonian Disorders (genetics) |
| 6 | Parkinson |
| 6 | Parkinson Disease, Secondary (diagnosis) |
| 6 | Pain (etiology) |
| 6 | Neurosurgical Procedures (methods) |
| 6 | Neurons (drug effects) |
| 6 | Myoclonus (diagnosis) |
| 6 | Myoclonus (complications) |
| 6 | Multicenter study |
| 6 | Movement Disorders (therapy) |
| 6 | Molecular Chaperones (genetics) |
| 6 | MPTP |
| 6 | L‐dopa |
| 6 | Involuntary movement |
| 6 | Huntington Disease (physiopathology) |
| 6 | Genetic determinism |
| 6 | Gene Frequency |
| 6 | Gait disorder |
| 6 | Freezing |
| 6 | Force |
| 6 | Family study |
| 6 | Evoked Potentials, Somatosensory (physiology) |
| 6 | Epidemiology |
| 6 | Electric Stimulation Therapy (methods) |
| 6 | Electric Stimulation Therapy (adverse effects) |
| 6 | Dystonic Disorders (genetics) |
| 6 | Dystonia (genetics) |
| 6 | Dyskinesia, Drug-Induced (therapy) |
| 6 | Dopamine receptor |
| 6 | Dopamine Agents (adverse effects) |
| 6 | Dopamine (physiology) |
| 6 | Dementia |
| 6 | Dementia (etiology) |
| 6 | Dementia (diagnosis) |
| 6 | Corpus Striatum (physiopathology) |
| 6 | Corpus Striatum (metabolism) |
| 6 | Chronic |
| 6 | Chorea (complications) |
| 6 | Cerebral infarction |
| 6 | Brain (blood supply) |
| 6 | Bilateral |
| 6 | Akinesia |
| 5 | validity |
| 5 | treatment |
| 5 | subthalamic nucleus stimulation |
| 5 | spinocerebellar ataxia |
| 5 | ropinirole |
| 5 | restless legs syndrome |
| 5 | reliability |
| 5 | psychometrics |
| 5 | myoclonus |
| 5 | monotherapy |
| 5 | genetics |
| 5 | essential tremor |
| 5 | apomorphine |
| 5 | apathy |
| 5 | Ubiquitin-Protein Ligases (genetics) |
| 5 | Subthalamic Nucleus (radiation effects) |
| 5 | Substantia Nigra (drug effects) |
| 5 | Stereotypy |
| 5 | Spinal Cord (physiopathology) |
| 5 | Spasticity |
| 5 | Sleep |
| 5 | Single photon emission tomography |
| 5 | Sex linked character |
| 5 | Sex Factors |
| 5 | Proteins (genetics) |
| 5 | Progressive |
| 5 | Primates |
| 5 | Pramipexole |
| 5 | Positron |
| 5 | Piribedil (therapeutic use) |
| 5 | Pilot Projects |
| 5 | Patient Selection |
| 5 | Pathogenesis |
| 5 | Parkinsonian Disorders (therapy) |
| 5 | Parkinsonian Disorders (epidemiology) |
| 5 | Parkinson Disease, Secondary (physiopathology) |
| 5 | Parkinson Disease (mortality) |
| 5 | Pain Measurement |
| 5 | Neuroprotective Agents (therapeutic use) |
| 5 | Neurons (pathology) |
| 5 | Nerve Tissue Proteins |
| 5 | Muscle Rigidity (etiology) |
| 5 | Multiple sclerosis |
| 5 | Movement Disorders (complications) |
| 5 | Movement (physiology) |
| 5 | Motor Cortex (physiopathology) |
| 5 | Motivation |
| 5 | Mitochondria |
| 5 | Mesencephalon (pathology) |
| 5 | Infant |
| 5 | Indoles (adverse effects) |
| 5 | Indication |
| 5 | Indans (therapeutic use) |
| 5 | Immunohistochemistry |
| 5 | Imaging, Three-Dimensional |
| 5 | Idiopathic |
| 5 | Huntington Disease (genetics) |
| 5 | Huntington Disease (complications) |
| 5 | History, 19th Century |
| 5 | Haplotypes |
| 5 | Hand |
| 5 | Guadeloupe (epidemiology) |
| 5 | Genetic Predisposition to Disease |
| 5 | Genetic Linkage |
| 5 | Frontal Lobe (physiopathology) |
| 5 | Freezing Reaction, Cataleptic (physiology) |
| 5 | Experimental disease |
| 5 | Executive function |
| 5 | Europe (epidemiology) |
| 5 | Encephalon |
| 5 | Electromyography (methods) |
| 5 | Electrodiagnosis |
| 5 | Dystonic Disorders (therapy) |
| 5 | Dystonia (chemically induced) |
| 5 | Dyskinesias (drug therapy) |
| 5 | Dopamine Agonists (administration & dosage) |
| 5 | Dopamine Agents (therapeutic use) |
| 5 | Diseases of the autonomic nervous system |
| 5 | Diagnostic and Statistical Manual of Mental Disorders |
| 5 | Depression (epidemiology) |
| 5 | Deep Brain Stimulation (instrumentation) |
| 5 | Cognition Disorders (psychology) |
| 5 | Chorea (pathology) |
| 5 | Chorea (etiology) |
| 5 | Chorea (drug therapy) |
| 5 | Cerebral cortex |
| 5 | Case control study |
| 5 | Brain Mapping (methods) |
| 5 | Brain (radionuclide imaging) |
| 5 | Botulinum Toxins (administration & dosage) |
| 5 | Biomechanical Phenomena |
| 5 | Apomorphine (therapeutic use) |
| 5 | Anticonvulsants (therapeutic use) |
| 5 | Amantadine (therapeutic use) |
| 4 | sleep |
| 4 | quality of life |
| 4 | neuroprotection |
| 4 | neurophysiology |
| 4 | motor complications |
| 4 | internal pallidum |
| 4 | freezing of gait |
| 4 | dyskinesias |
| 4 | dopamine agonist |
| 4 | diagnosis |
| 4 | dementia |
| 4 | cognition |
| 4 | clinical trial |
| 4 | anxiety |
| 4 | alpha-Synuclein (genetics) |
| 4 | Walking (physiology) |
| 4 | Unilateral |
| 4 | Tyrosine 3-Monooxygenase (metabolism) |
| 4 | Tremor (pathology) |
| 4 | Tremor (diagnosis) |
| 4 | Treatment efficiency |
| 4 | Tomography, Emission-Computed, Single-Photon (methods) |
| 4 | Terminology as Topic |
| 4 | Technique |
| 4 | Stereotaxy |
| 4 | Spinocerebellar Ataxias (diagnosis) |
| 4 | Speech |
| 4 | Single-Blind Method |
| 4 | Selegiline (therapeutic use) |
| 4 | SPECT |
| 4 | Receptors, Dopamine D2 (drug effects) |
| 4 | Rats, Sprague-Dawley |
| 4 | REM Sleep Behavior Disorder (diagnosis) |
| 4 | Protein-Serine-Threonine Kinases (genetics) |
| 4 | Positron-Emission Tomography |
| 4 | Positron-Emission Tomography (methods) |
| 4 | Piribedil (administration & dosage) |
| 4 | Piperazines (therapeutic use) |
| 4 | Pergolide |
| 4 | Pergolide (therapeutic use) |
| 4 | Performance evaluation |
| 4 | Pathology |
| 4 | Parkinsonian Disorders (chemically induced) |
| 4 | Parkinson Disease (metabolism) |
| 4 | Parkin |
| 4 | Nuclear Proteins (genetics) |
| 4 | Neurotoxin |
| 4 | Neurophysiology |
| 4 | Neurons (metabolism) |
| 4 | Neurodegenerative Diseases (physiopathology) |
| 4 | Neurodegenerative Diseases (complications) |
| 4 | Neural Pathways (physiopathology) |
| 4 | Neural Pathways (physiology) |
| 4 | Neural Pathways (anatomy & histology) |
| 4 | Neural Inhibition (physiology) |
| 4 | Nerve Degeneration (pathology) |
| 4 | Myoclonus (genetics) |
| 4 | Myoclonus (etiology) |
| 4 | Multivariate Analysis |
| 4 | Multiple System Atrophy (epidemiology) |
| 4 | Multiple Sclerosis (complications) |
| 4 | Movement Disorders (physiopathology) |
| 4 | Mouse |
| 4 | Motor cortex |
| 4 | Motor Skills (drug effects) |
| 4 | Motor Activity (drug effects) |
| 4 | Mice, Transgenic |
| 4 | Mental Disorders (etiology) |
| 4 | Medical screening |
| 4 | Mechanism of action |
| 4 | McLeod syndrome |
| 4 | Malignant tumor |
| 4 | Macaca fascicularis |
| 4 | MacLeod syndrome |
| 4 | MRI |
| 4 | Logistic Models |
| 4 | Locus niger |
| 4 | Huntington Disease (diagnosis) |
